Related Experiment Videos
Age and dose interval as factors in agglutinin formation to pertussis vaccine
Insights
Optimal agglutinin response to diphtheria-tetanus-pertussis (DTP) vaccine is achieved by starting immunization at five months or later. A minimum eight-week interval between doses further enhances antibody production in infants.
Area of Science:
- Immunology
- Pediatrics
- Vaccinology
Background:
- The diphtheria-tetanus-pertussis (DTP) vaccine is crucial for infant immunization.
- Understanding optimal timing for DTP vaccination is essential for robust immune responses.
Purpose of the Study:
- To determine the optimal age and dose interval for eliciting an agglutinin response to pertussis antigens in the DTP vaccine.
- To evaluate how age at initial vaccination and inter-dose intervals impact antibody production.
Main Methods:
- Infants were inoculated with DTP vaccine at varying ages (4 weeks to 8 months) for the initial dose.
- Subsequent dose intervals were systematically varied.
- Agglutinin titers against pertussis antigens were measured to assess immune response.
Main Results:
- Starting DTP immunization at five months of age or later resulted in the best agglutinin production.
- A minimum interval of eight weeks between the first and second DTP doses was associated with optimum antibody levels.
- Deviations from these age and interval parameters reduced the likelihood of an optimal agglutinin response.
Conclusions:
- The timing of initial DTP vaccination and the interval between doses significantly influence the infant's agglutinin response.
- Recommendations for DTP immunization schedules should consider these findings to maximize vaccine efficacy.
- Later initiation of DTP vaccination (≥5 months) and adequate inter-dose spacing (≥8 weeks) are key for optimal pertussis antibody development.
Abstract:
The agglutinin response to pertussis agglutinogens in diphtheria-tetanus-pertussis (DTP) vaccine was determined in human infants inoculated initially at ages four weeks to eight months. The effects of age at the time of initial dose and the interval between subsequent doses were specifically evaluated. Our findings demonstrate that optimum agglutinin production is best achieved with DTP vaccine by beginning immunization at five months of age or later followed by a second dose at eight weeks or more. Variation in the two variables, age and dose interval, decreases the likelihood of an optimum agglutinin response.